Seattle Genetics (SGEN) PT Raised to $165 at Stifel After Considering Merck Contribution

September 22, 2020 6:44 AM
Stifel analyst Stephen Willey raised the price target on Seattle Genetics (NASDAQ: SGEN) to $165.00 (from $145.00) after updating the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst PT Change